How Attractive Is Astellas Pharma After a 44.1% Surge and Mixed Valuation Signals? [Yahoo! Finance]
ASTELLAS PHARMA UNSP/ADR (ALPMY)
NASDAQ:AMEX Investor Relations:
astellas.com/jp/en/investors
Company Research
Source: Yahoo! Finance
In this article, we walk through what the market is pricing in and where the gaps might be. The stock is up 44.1% over the last year and 36.5% year to date, even after a recent 1.2% dip in the past week and a 6.1% gain over the last month. Behind those moves, investors have been reacting to Astellas Pharma's evolving drug pipeline and strategic portfolio shifts. These developments signal how the business could look several years from now. Ongoing updates around late stage clinical programs and regulatory milestones have also nudged sentiment, shaping expectations for future cash flows and risk. Right now, Astellas Pharma scores just 2/6 on our undervaluation checks, which means some metrics hint at value while others look more fully priced. Next, we will unpack the different valuation lenses investors use, and then finish with a more holistic way to think about what this stock is really worth. Astellas Pharma scores just 2/6 on our valuation checks. See what other red flags we
Show less
Read more
Impact Snapshot
Event Time:
ALPMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALPMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALPMY alerts
High impacting ASTELLAS PHARMA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
ALPMY
News
- Positive Phase 3 PADCEV–Keytruda Bladder Cancer Data Could Be A Game Changer For Astellas Pharma (TSE:4503) [Yahoo! Finance]Yahoo! Finance
- Reassessing Astellas Pharma (TSE:4503) Valuation After Positive PADCEV-Keytruda Phase 3 Bladder Cancer Results [Yahoo! Finance]Yahoo! Finance
- Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines [Yahoo! Finance]Yahoo! Finance
- Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium [Yahoo! Finance]Yahoo! Finance
- Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers SymposiumPR Newswire